Trump Administration Approves Nvidia H200 AI Chip Sales to China Under New Export Rules 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
Saks Global Files for Bankruptcy Protection Amid Mounting Luxury Retail Pressures 
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand 
AbbVie Commits $100 Billion to U.S. Investment in Drug Pricing Deal With Trump Administration 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
Amazon Reviews Supplier Costs as U.S.–China Tariffs Ease 
Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition 
Nvidia Denies Upfront Payment Requirement for H200 AI Chips Amid China Export Scrutiny 
AFT Leaves X Over AI-Generated Images of Minors 
Lynas CEO Amanda Lacaze to Retire After 12 Years as Rare Earths Demand Grows 
Zhipu AI Launches GLM-Image Model Trained on Huawei Chips, Boosting China’s AI Self-Reliance Drive 
Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes 
U.S. Government Invests $1 Billion in L3Harris Rocket Motor Business to Secure Missile Supply Chain 
Starlink Internet Remains Active in Iran Despite Nationwide Blackout 
Tesla, EEOC Move Toward Mediation in Racial Harassment Lawsuit 
KING OF PRUSSIA, Pa., March 29, 2017 -- Trevena, Inc. (NASDAQ:TRVN) today announced that it will be presenting at Needham & Company’s 16th Annual Healthcare Conference on Wednesday, April 5, 2017 at 10:00 a.m. EDT in New York.
To join a live audio webcast of the presentation, please visit the Investor section of the Company’s website. Following the conclusion of the presentation, the webcast will be available for replay for 30 days.
About Trevena
Trevena, Inc. is a biopharmaceutical company developing innovative therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. The Company has discovered four novel and differentiated drug candidates, including OLINVO™ (oliceridine injection). Trevena also has discovered TRV250, in preclinical development for the treatment of migraine, and TRV734, for pain. The Company is actively working on an early stage portfolio of drug discovery programs.
Contacts Trevena, Inc. Investors: Jonathan Violin, Ph.D. Sr. Director, Investor Relations 610-354-8840 x231 [email protected] or Media: Public Relations [email protected]
